Olufemi Taiwo, MD
Child & Adolescent Psychiatry · Fayetteville, GANPI 1225005598
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 282 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 28.5% of the total. Reporting peaked in 2023 at $875 and has fallen 85.0% since, to $131 in 2025. Among child & adolescent psychiatry clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 282 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$664
- Otsuka America Pharmaceutical, Inc.$448
- Takeda Pharmaceuticals U.S.A., Inc.$330
- Tris Pharma Inc$222
- Sunovion Pharmaceuticals Inc.$219
- plus $1K from 19 others
Across 96 payments — averaging $1751.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$65K
- Neurocrine Biosciences, Inc.$46K
- AbbVie$32K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$26K
What the payments were for
- Food & beverage$4,553100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $1,295 |
| Johnson & Johnson | 33 | $664 |
| Otsuka America Pharmaceutical, Inc. | 25 | $448 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $330 |
| Tris Pharma Inc | 9 | $222 |
| Sunovion Pharmaceuticals Inc. | 15 | $219 |
| Teva Pharmaceuticals USA, Inc. | 12 | $183 |
| Lundbeck LLC | 8 | $157 |
| Ironshore Pharmaceuticals Inc. | 6 | $117 |
| Indivior Inc. | 4 | $91 |
| Supernus Pharmaceuticals, Inc. | 5 | $91 |
| Neurocrine Biosciences, Inc. | 5 | $89 |
| Almatica Pharma LLC | 5 | $88 |
| Axsome Therapeutics, Inc. | 4 | $85 |
| Vanda Pharmaceuticals Inc. | 4 | $84 |
| Corium, LLC | 5 | $77 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $65 |
| Alkermes, Inc. | 3 | $51 |
| Neos Therapeutics, LP | 3 | $46 |
| Shire North American Group Inc | 2 | $38 |
| Vertical Pharmaceuticals, LLC | 2 | $33 |
| Avanir Pharmaceuticals, Inc. | 1 | $29 |
| Eisai Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Brainsway USA Inc | 1 | $11 |
How this compares
$4,553 in reported general payments places this provider in the 90th percentile of 91 child & adolescent psychiatry providers in Georgia.
See all child & adolescent psychiatry providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 25 | $79,867 |
| VraylarCariprazine Hcl | 32 | $55,481 |
| Aripiprazole | 171 | $16,040 |
| Lurasidone Hcl | 71 | $11,088 |
| TrintellixVortioxetine Hydrobromide | 11 | $8,147 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $5,843 |
| Paliperidone ErPaliperidone | 24 | $3,825 |
| Duloxetine Hcl | 281 | $3,534 |
| Vilazodone Hcl | 63 | $3,367 |
| Lisdexamfetamine Dimesylate | 12 | $3,066 |
| Clozapine | 30 | $2,676 |
| Quetiapine Fumarate | 177 | $2,601 |
| Divalproex Sodium ErDivalproex Sodium | 94 | $2,536 |
| Buspirone Hcl | 159 | $2,528 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 44 | $2,476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $664 | $79,86725 claims |
| AbbVieVraylar | $1,295 | $55,48132 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $330 | $13,99026 claims |
| Almatica Pharma LLCSertraline Hcl | $88 | $878147 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $183 | $69112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 91 child & adolescent psychiatry providers in Georgia.
Other child & adolescent psychiatry in Fayetteville
- Suneel KatragaddaAtlanta$460K
- Kevin WindersSavannah$225K
- Annamarie PaulsenConyers$25K
- Haolat BabalakinBerkeley Lake$16K
- Heerain ShahSuwanee$14K
- Olujimi AdefisanAtlanta$14K
- Deepti BhasinWarner Robins$11K
- Mhd AlkhatibAtlanta$7K
- Mary HuberAtlanta$7K
- Jocelyn BaylissAugusta$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.